Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Esperion Therapeutics, Inc. (ESPR) had Consolidated Net Income/Loss of $-40.45M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$65.00M |
|
$-40.45M |
|
$31.54M |
|
$33.46M |
|
$87.09M |
|
$-22.10M |
|
$-18.36M |
|
$-40.45M |
|
$-40.45M |
|
$-40.45M |
|
$-40.45M |
|
|
Consolidated Net Income/Loss |
$-40.45M |
$-40.45M |
|
$-22.10M |
|
$-21.37M |
|
196.13M |
|
196.13M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$318.78M |
|
$0.23M |
|
$5.25M |
|
$324.03M |
|
$270.97M |
|
$238.32M |
|
$479.27M |
|
$750.24M |
|
$-426.21M |
|
$-426.27M |
|
$-426.21M |
|
196.66M |
|
| Cash Flow Statement Financials | |
$-22.63M |
|
-- |
|
$-7.50M |
|
$144.76M |
|
$114.63M |
|
$-30.13M |
|
$2.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.18 |
|
-- |
|
-- |
|
-1.27 |
|
-0.69 |
|
51.48% |
|
-34.00% |
|
-34.00% |
|
-- |
|
-62.24% |
|
-62.24% |
|
$-22.63M |
|
-- |
|
-- |
|
-- |
|
0.20 |
|
0.32 |
|
0.80 |
|
112.57 |
|
9.49% |
|
9.49% |
|
-12.48% |
|
21.53% |
|
$-2.17 |
|
$-0.12 |
|
$-0.12 |
|